Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Sponsors » Advances in Clinical Genomics Profiling » NCCN Backs Molecular Testing for Prostate Cancer Patients in Certain Risk Groups

NCCN Backs Molecular Testing for Prostate Cancer Patients in Certain Risk Groups

Mar 18, 2020
|
staff reporter

This article was updated to note that the Decipher test is sold by Decipher Biosciences, not GenomeDx Biosciences. 

NEW YORK – The National Comprehensive Cancer Network has updated prostate cancer guidelines to recommend biomarker testing for patients with unfavorable intermediate or high risk for aggressive disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Not Counting These

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Caputo on Leave

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

The Timing of a Vaccine

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

Nature Papers Report on Mass Spec Repository, Tumor Signaling Maps, Viking Genetics

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.

Sep
23
Featured Webinar

Fluorescent Amplification for Next Generation Sequencing Library Preparation: A Streamlined Workflow to Improve NGS Quality Control Testing

Sponsored by
Beckman Coulter

This webinar will discuss a streamlined library preparation method for next-generation sequencing (NGS) that improves quality control testing capability while reducing the total number of steps compared to conventional multiplexed library workflows.

Sep
24
Featured Webinar

New Insights Underscore the Need to Identify NTRK Fusions in Childhood Tumors

Sponsored by
ArcherDX

NTRK fusions are oncogenic drivers in a variety of tumors.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

What's Popular?

In Molecular Diagnostics

  1. Illumina's Stock Falls 9 Percent on Grail Acquisition Rumors

  2. FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

    Premium

  3. Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

  4. Grail Plans Additional Liquid Biopsy Tests for Cancer Detection, Monitoring

    Premium

  5. New York City Opening Dedicated COVID-19 Testing Laboratory

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.